>Mercado global de doenças da bexiga, por tipo (cistite, incontinência urinária, bexiga hiperativa, cistite intersticial, cancro da bexiga), tipo de tratamento (cirurgia, medicação, não cirúrgico), utilizador final (hospitais, clínicas, centros de cirurgia ambulatória , outros), distribuição Canal (Direto, Retalho) - Tendências do Setor e Previsão para 2029.
Análise e insights do mercado de distúrbios da bexiga
Os distúrbios da bexiga são um grupo de distúrbios que podem afetar as atividades diárias da vida humana. Alguns dos distúrbios da bexiga mais comuns são a cistite – em que a bexiga está infetada e causa inflamação. Incontinência urinária – perda de controlo da bexiga, cistite intersticial – dor na bexiga e micção frequente e urgente, e bexiga hiperativa – uma condição em que a bexiga comprime a urina. Os distúrbios da bexiga podem afetar a qualidade de vida e causar outros problemas de saúde. Alterações e problemas de saúde, incluindo fatores do sistema nervoso e do estilo de vida, podem causar ou contribuir para a IU em homens e mulheres.
Os distúrbios da bexiga mais comuns são a bexiga hiperativa e a IU. Estes problemas estão associados ao sistema nervoso. Os nervos transportam mensagens do cérebro para a bexiga, indicando contração ou libertação dos músculos.
O mercado global de distúrbios da bexiga deverá crescer no período de previsão de 2022 a 2029. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 11,4% no período de previsão de 2022 a 2029 e deverá atingir os 22.342,48 milhões de dólares até 2029.
|
Métrica de reporte |
Detalhes |
|
Período de previsão |
2022 a 2029 |
|
Ano base |
2021 |
|
Anos históricos |
2020 (personalizável 2019-2014) |
|
Unidades Quantitativas |
Receita em milhões de dólares |
|
Segmentos cobertos |
Por Tipo (Cistite, Incontinência Urinária, Bexiga Hiperativa, Cistite Intersticial, Cancro da Bexiga), Tipo de Tratamento (Cirurgia, Medicamentoso, Não Cirúrgico), Utilizador Final (Hospitais, Clínicas, Centros Cirúrgicos de Ambulatório, Outros), Canal de Distribuição (Direto , Retalho ) |
|
Países abrangidos |
EUA, Canadá, México, Alemanha, Reino Unido, França, Itália, Espanha, Turquia, Rússia, Holanda, Suíça, Blegium e resto da Europa, China, Japão, Índia, Coreia do Sul, Austrália, Singapura, Tailândia, Malásia, Indonésia , Filipinas , Vietname, Resto da Ásia-Pacífico, Brasil, Argentina, Peru, Resto da América do Sul, África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egito, Israel, Resto do Médio Oriente e África |
|
Participantes do mercado abrangidos |
As principais empresas que operam no mercado são a Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (uma subsidiária da KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Valencia Technologies, Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Grupo Zydus, Swati Spentose, Urovant Sciences entre outros. |
Definição de mercado do mercado global de distúrbios da bexiga
Bladder related disorders include cystitis - inflammation of the bladder, often from an infection, Urinary incontinence - loss of bladder control, Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.
Different tests are performed by the doctors to diagnose the bladder disorder that includes x-rays, urine tests, and a bladder wall examination by scope called cystoscope. The treatment of the disorder depends on the cause of the problem and the treatment includes medication, surgeries (in severe cases), and non-surgical procedures.
Anticholinergic medications are the first-line of pharmacotherapy in Overactive Bladder (OAB) syndrome. OAB is a clinical symptom characterized by urgency of desire to urine pass, which is difficult to defer, generally frequency to pass urine more than eight times per day are consider into OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle that reduce the bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.
Global Bladder Disorders Market Dynamics
Drivers
-
STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
Bladder disorders are a number of bladder issues that can affect daily physical activities. The most common bladder disorders are cystitis, interstitial cystitis, overactive bladder, urinary incontinence, and bladder cancer. Most bladder issues are caused by a bacterial infection that enters the urinary tract.
Various strategic initiatives by the market players in terms of collaboration, acquisition, partnership, and others, allow them to increase their company's product portfolio, leading to market expansion and hence enhancing the product demand among customers, which ultimately provides the market players to earn maximum revenue.
-
GROWING GERIATRIC POPULATION
Aging is a strong risk factor that can associate with bladder-related disorders. Aging prompts neurologic, anatomic, and biochemical changes in bladder function, which can result in the development of OAB. Overactive bladder is the most common problem among the geriatric population. Aging population is suffering from various bladder-associated problems and disorders due to which they are the predominant users of chronic health management services and solutions.
According to the noble study, the prevalence rate of overactive bladder is approximately 16.9 in women and men, around 16.0%, and the prevalence of OAB is growing with age. However, treatment guidelines specify the preferred first-, second-, and third-line OAB therapy strategies. Bladder disorders are associated with Neurologic disorders such as dementia, and in this age group, OAB is very challenging for the senior population. Over the last few decades, the old age population has been drastically growing worldwide.
-
RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS
Various treatment options and innovative therapies are available for OAB and other bladder disorders. Many biopharmaceutical and pharmaceutical companies are investing in various unconventional therapies for bladder disorders, which are expected to launch during the forecast period.
-
COMBINATION OF DIFFERENT TARGET THERAPIES
Combination Therapies are much more effective than monotherapy, without additional side effects. Combination Therapies are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieve patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.
Opportunities
-
SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS
Chronic diseases are considered one of the major leading causes of death in developing countries worldwide. Therefore, the importance of healthcare management of chronic management is increased among public health practitioners.
Bladder disorder management now places a strong emphasis on assisting patients with a range of alternatives for self-care and a range of consultation services to educate patients about their illness state and move forward. These therapies also assist patients in getting over emotional trauma and anxiety, which may act as a counter-protective mechanism.
Rising technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic bladder disorders. Since they are not required to stay in the hospital for an extended period of time, they have also decreased costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Considering the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in managing chronic diseases to enhance patient outcomes.
-
RISING DISEASE MANAGEMENT PROGRAMS
People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. The rise in the number of people living longer with many chronic problems and increasing healthcare expenditures has encouraged better healthcare plans.
Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people.
Restraints/Challenges
However, the difficulty in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures. The cost of the procedure generally gets elevated because of the high cost of the advanced technological devices used in the treatment, which is expected to restrain the market growth.
This bladder disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Global bladder disorders market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.
Post COVID-19 Impact on Global Bladder Disorders Market
COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market
Recent Development
- In June 2022, Valencia Technologies Corporation announced the implantable neuromodulation technology product eCoin®, which is reshaping the delivery of long-term therapy for bladder control, is a tibial implant for Urge Urinary Incontinence (UUI). eCoin® received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) in March 2022, making it the first and only FDA-approved implantable tibial neurostimulator indicated for the treatment of urge urinary incontinence (UUI). This new product has helped the company to increase its portfolio
Global Bladder Disorders Market Scope
Global bladder disorders market is segmented into treatment, end user, and distribution channel types. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Type
- Cystitis
- Urinary Incontinence
- Overactive Bladder
- Interstitial Cystitis
- Bladder Cancer
On the basis of type, the global bladder disorders market is segmented into cystitis, urinary incontinence, overactive bladder, interstitial cystitis, bladder cancer.
Treatment type
- Surgery
- Medications
- Others
On the basis of product, the global bladder disorders market is segmented into surgery, medication, and others.
End User
- Hospital
- Clinics
- Ambulatory Surgery centers
- Others
On the basis of end users, the global bladder disorders market is segmented into hospitals, clinics, ambulatory surgery centers, and others.
Distribution Channel
- Direct
- Retail
On the basis of distribution channel, the global bladder disorders market is segmented into direct and retail.
Global Bladder Disorders Market Regional Analysis/Insights
The global bladder disorders market is analyzed, and market size insights and trends are provided by country, type, treatment type, end user, and distribution channel, as referenced above.
Countries covered in this market are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Turkey, Russia, Netherlands, Switzerland, Belgium and Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of the Middle East and Africa.
North America dominates the global bladder disorders market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of overactive bladder disorder in the region, and growing R&D investments and the launch of novel therapies are boosting the market
A secção do país do relatório também fornece fatores individuais de impacto no mercado e alterações nas regulamentações do mercado que impactam as tendências atuais e futuras do mercado. Pontos de dados, como vendas de novos e de reposição, demografia do país, epidemiologia de doenças e tarifas de importação e exportação, são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, são considerados a presença e disponibilidade de marcas globais e os desafios enfrentados devido à elevada concorrência de marcas locais e nacionais e o impacto dos canais de vendas, ao mesmo tempo que se fornece uma análise de previsão dos dados do país.
Análise do panorama competitivo e da quota de mercado global de distúrbios da bexiga
O panorama competitivo do mercado global de distúrbios da bexiga fornece detalhes sobre os concorrentes. Os detalhes incluem a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento do produto, largura e amplitude do produto e aplicação domínio. Os dados acima estão apenas relacionados com o foco da empresa no mercado global de distúrbios da bexiga.
Alguns dos principais players que operam no mercado global de doenças da bexiga são a Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Blue Wind Medical, Valencia Technologies, Gaylord Chemical Company, LLC, Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Ciências entre outros.
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem a grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise da quota de mercado da empresa, padrões de medição, global vs. Solicite uma chamada de analista em caso de dúvidas adicionais.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BLADDER DISORDERS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 GLOBAL BLADDER DISORDERS MARKET, PIPELINE ANALYSIS
5 GLOBAL BLADDER DISORDER MARKET: REGULATIONS
5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION
5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS
5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS
6 GLOBAL BLADDER DISORDERS MARKET OVERVIEW
6.1 DRIVERS
6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS
6.1.2 GROWING GERIATRIC POPULATION
6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS
6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES
6.2 RESTRAINTS
6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT
6.2.2 PRODUCTS RECALLS FROM MARKET
6.3 OPPORTUNITIES
6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS
6.3.2 RISING DISEASE MANAGEMENT PROGRAMS
6.4 CHALLENGES
6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS
6.4.2 PATENT EXPIRY OF DRUGS
7 GLOBAL BLADDER DISORDERS MARKET, BY TYPE
7.1 OVERVIEW
7.2 OVERACTIVE BLADDER
7.3 URINARY INCONTINENCE
7.4 CYSTITIS
7.5 INTERSTITIAL CYSTITIS
7.6 BLADDER CANCER
7.7 OTHERS
8 GLOBAL BLADDER DISORDERS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 MEDICATION
8.2.1 TOLTERODINE
8.2.2 MIRABEGRON
8.2.3 FESOTERODINE
8.2.4 OXYBUTYNIN
8.2.5 SOLIFENACIN
8.2.6 DARIFENACIN
8.2.7 TROSPIUM
8.2.8 OTHERS
8.3 SURGERY
8.3.1 SURGERY TO INCREASE BLADDER CAPACITY
8.3.2 BLADDER REMOVAL
8.3.3 OTHERS
8.4 OTHERS
9 GLOBAL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 DIRECT
9.3 RETAIL
10 GLOBAL BLADDER DISORDERS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 CLINICS
10.4 AMBULATORY SURGICAL CENTERS
10.5 OTHERS
11 GLOBAL BLADDER DISORDERS MARKET, BY GEOGRAPHY
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.2.3 MEXICO
11.3 EUROPE
11.3.1 GERMANY
11.3.2 U.K.
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 TURKEY
11.3.7 RUSSIA
11.3.8 NETHERLANDS
11.3.9 SWITZERLAND
11.3.10 BELGIUM
11.3.11 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 AUSTRALIA
11.4.5 SOUTH KOREA
11.4.6 THAILAND
11.4.7 SINGAPORE
11.4.8 INDONESIA
11.4.9 MALAYSIA
11.4.10 VIETNAM
11.4.11 PHILIPPINES
11.4.12 REST OF ASIA-PACIFIC
11.5 SOUTH AMERICA
11.5.1 BRAZIL
11.5.2 ARGENTINA
11.5.3 REST OF SOUTH AMERICA
11.6 MIDDLE EAST AND AFRICA
11.6.1 SAUDI ARABIA
11.6.2 SOUTH AFRICA
11.6.3 UAE
11.6.4 EGYPT
11.6.5 ISRAEL
11.6.6 REST OF MIDDLE EAST AND AFRICA
12 GLOBAL BLADDER DISORDERS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 MERCK AND CO. INC. (2021)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 ASTELLAS PHARMA INC. (2021)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 BRISTOL-MYERS SQUIBB COMPANY (2021)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 BOSTON SCIENTIFIC CORPORATION (2021)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 VIATRIS INC. (2021)
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 ABBVIE (2021)
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 AXONICS, INC. (2021)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 BLUE WIND MEDICAL (2021)
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 COLOPLAST CORP. (2021)
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.1 GAYLORD CHEMICAL COMPANY, LLC (2021)
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 JOHNSON & JOHNSON SERVICES, INC. (2021)
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021)
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 LABORIE (2021)
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MEDTRONIC (2021)
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 PFIZER INC. (2021)
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 VALENCIA TECHNOLOGIES (2021)
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021)
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 SWATI SPENTOSE (2021)
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 UROVANT SCIENCES (2021)
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 ZYDUS GROUP (2021)
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tabela
TABLE 1 GLOBAL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 GLOBAL OVERACTIVE BLADDER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 GLOBAL URINARY INCONTINENCE IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 GLOBAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 GLOBAL INTERSTITIAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 GLOBAL BLADDER CANCER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 GLOBAL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 9 GLOBAL MEDICATION IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 GLOBAL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 11 GLOBAL SURGERY IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 GLOBAL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 13 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 GLOBAL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 15 GLOBAL DIRECT IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 GLOBAL RETAIL IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 GLOBAL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 GLOBAL HOSPITALS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 GLOBAL CLINICS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 GLOBAL AMBULATORY SURGICAL CENTERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 GLOBAL OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 GLOBAL BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 30 U.S. BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 U.S. BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 32 U.S. MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 33 U.S. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 34 U.S. BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 35 U.S. BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 36 CANADA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 CANADA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 38 CANADA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 39 CANADA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 40 CANADA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 CANADA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 MEXICO BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 MEXICO BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 44 MEXICO MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 MEXICO SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 46 MEXICO BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 47 MEXICO BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 48 EUROPE BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 49 EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 EUROPE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 51 EUROPE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 52 EUROPE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 53 EUROPE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 54 EUROPE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 55 GERMANY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 GERMANY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 57 GERMANY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 58 GERMANY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 59 GERMANY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 60 GERMANY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 61 U.K. BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 U.K. BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 63 U.K. MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 64 U.K. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 65 U.K. BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 66 U.K. BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 67 FRANCE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 FRANCE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 69 FRANCE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 70 FRANCE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 71 FRANCE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 72 FRANCE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 73 ITALY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 ITALY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 75 ITALY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 76 ITALY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 77 ITALY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 78 ITALY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 79 SPAIN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 SPAIN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 81 SPAIN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 82 SPAIN. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 83 SPAIN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 SPAIN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 TURKEY BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 TURKEY BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 87 TURKEY MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 88 TURKEY SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 89 TURKEY BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 90 TURKEY BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 91 RUSSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 RUSSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 93 RUSSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 94 RUSSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 95 RUSSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 RUSSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 NETHERLANDS BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 NETHERLANDS BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 99 NETHERLANDS MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 100 NETHERLANDS SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 101 NETHERLANDS BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 102 NETHERLANDS BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 103 SWITZERLAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 SWITZERLAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 105 SWITZERLAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 106 SWITZERLAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 107 SWITZERLAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 108 SWITZERLAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 109 BELGIUM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 BELGIUM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 111 BELGIUM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 112 BELGIUM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 113 BELGIUM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 114 BELGIUM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 115 REST OF EUROPE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 117 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 119 ASIA-PACIFIC MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 120 ASIA-PACIFIC SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 121 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 122 ASIA-PACIFIC BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 CHINA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 CHINA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 125 CHINA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 126 CHINA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 127 CHINA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 128 CHINA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 129 JAPAN BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 JAPAN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 131 JAPAN MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 132 JAPAN SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 133 JAPAN BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 134 JAPAN BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 135 INDIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 INDIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 137 INDIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 138 INDIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 139 INDIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 INDIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 AUSTRALIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 142 AUSTRALIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 143 AUSTRALIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 144 AUSTRALIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 145 AUSTRALIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 146 AUSTRALIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 147 SOUTH KOREA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 SOUTH KOREA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 149 SOUTH KOREA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 150 SOUTH KOREA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 151 SOUTH KOREA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 152 SOUTH KOREA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 153 THAILAND BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 154 THAILAND BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 155 THAILAND MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 156 THAILAND SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 157 THAILAND BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 158 THAILAND BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 159 SINGAPORE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 SINGAPORE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 161 SINGAPORE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 162 SINGAPORE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 163 SINGAPORE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 164 SINGAPORE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 165 INDONESIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 INDONESIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 167 INDONESIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 168 INDONESIA. SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 169 INDONESIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 170 INDONESIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 171 MALAYSIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 MALAYSIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 173 MALAYSIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 174 MALAYSIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 175 MALAYSIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 176 MALAYSIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 177 VIETNAM BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 VIETNAM BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 179 VIETNAM MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 180 VIETNAM SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 181 VIETNAM BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 182 VIETNAM BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 183 PHILIPPINES BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 184 PHILIPPINES BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 185 PHILIPPINES MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 186 PHILIPPINES SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 187 PHILIPPINES BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 188 PHILIPPINES BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 189 REST OF ASIA-PACIFIC BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 SOUTH AMERICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 191 SOUTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 SOUTH AMERICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 193 SOUTH AMERICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 194 SOUTH AMERICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 195 SOUTH AMERICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 196 SOUTH AMERICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 197 BRAZIL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 BRAZIL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 199 BRAZIL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 200 BRAZIL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 201 BRAZIL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 202 BRAZIL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 203 ARGENTINA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 204 ARGENTINA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 205 ARGENTINA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 206 ARGENTINA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 207 ARGENTINA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 208 ARGENTINA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 209 REST OF SOUTH AMERICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 211 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 213 MIDDLE EAST AND AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 214 MIDDLE EAST AND AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 215 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 216 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 217 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 218 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 219 SAUDI ARABIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 220 SAUDI ARABIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 221 SAUDI ARABIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 222 SAUDI ARABIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 223 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 225 SOUTH AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 226 SOUTH AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 227 SOUTH AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 228 SOUTH AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 229 UAE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 UAE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 231 UAE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 232 UAE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 233 UAE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 234 UAE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 235 EGYPT BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 EGYPT BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 237 EGYPT MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 238 EGYPT SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 239 EGYPT BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 240 EGYPT BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 241 ISRAEL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 ISRAEL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 243 ISRAEL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 244 ISRAEL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 245 ISRAEL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 246 ISRAEL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 247 REST OF MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)
Lista de Figura
FIGURE 1 GLOBAL BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 2 GLOBAL BLADDER DISORDERS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL BLADDER DISORDERS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL BLADDER DISORDERS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL BLADDER DISORDERS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL BLADDER DISORDERS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL BLADDER DISORDERS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL BLADDER DISORDERS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL BLADDER DISORDERS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL BLADDER DISORDERS MARKET: SEGMENTATION
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF BLADDER DISORDERS EXPECTED TO DRIVE THE GLOBAL BLADDER DISORDERS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 OVERACTIVE BLADDER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BLADDER DISORDERS MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BLADDER DISORDERS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR BLADDER DISORDERS MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL BLADDER DISORDER MARKET
FIGURE 16 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, 2021
FIGURE 17 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 18 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 GLOBAL BLADDER DISORDERS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2021
FIGURE 21 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)
FIGURE 22 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 23 GLOBAL BLADDER DISORDERS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 25 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 26 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 27 GLOBAL BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 28 GLOBAL BLADDER DISORDERS MARKET: BY END USER, 2021
FIGURE 29 GLOBAL BLADDER DISORDERS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 30 GLOBAL BLADDER DISORDERS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 31 GLOBAL BLADDER DISORDERS MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 GLOBAL BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 33 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2021)
FIGURE 34 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2022 & 2029)
FIGURE 35 GLOBAL BLADDER DISORDERS MARKET: BY REGION (2021 & 2029)
FIGURE 36 GLOBAL BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 37 NORTH AMERICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 38 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 39 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 40 NORTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 41 NORTH AMERICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 42 EUROPE BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 43 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 44 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 EUROPE BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 EUROPE BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 47 ASIA-PACIFIC BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 48 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 49 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 50 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 51 ASIA-PACIFIC BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 52 SOUTH AMERICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 53 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 54 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 55 SOUTH AMERICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 56 SOUTH AMERICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 57 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)
FIGURE 58 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)
FIGURE 59 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 60 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 61 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)
FIGURE 62 GLOBAL BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
FIGURE 63 NORTH AMERICA BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
FIGURE 64 EUROPE BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
FIGURE 65 ASIA-PACIFIC BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
